Role of phytochemicals in the prevention of menopausal bone loss: Evidence from in vitro and in vivo, human interventional and pharmacokinetic studies

Current Medicinal Chemistry

Volumn 16, Issue 9, 2009, Pages 1138-1157

  Sharan, Kunal ^a   Siddiqui, Jawed A ^a   Swarnkar, Gaurav ^a   Maurya, Rakesh ^a   Chattopadhyay, Naibedya ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Adipogenic; Anti resorptive; Bioavailabilty; Estrogenicity; Osteogenic

Indexed keywords

APIGENIN; AURANTIIN; BETA CRYPTOXANTHIN; BIOCHANIN A; CATECHIN; COUMESTROL; DAIDZEIN; EPIGALLOCATECHIN GALLATE; GENISTEIN; GLYCITEIN; HESPERETIN; HESPERIDIN; ICARIIN; IPRIFLAVONE; ISOFLAVONE DERIVATIVE; ISOTAXIRESINOL; KAEMPFEROL; LIGNAN; LUTEOLIN; LYCOPENE; MYRICETIN; NORDIHYDROGUAIARETIC ACID; PLACEBO; QUERCETIN; RESVERATROL; RETINOIC ACID; RUTOSIDE; STILBENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITISIN A;

ADIPOCYTE; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; BONE MINERALIZATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PHYTOTHERAPY; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY PREVENTION; PROTECTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; MOLECULAR STRUCTURE; OSTEOPOROSIS, POSTMENOPAUSAL; PLANT EXTRACTS;

EID: 65649144771     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787581806     Document Type: Review

References (197)

1. Maggio, M. Estrogen replacement therapy and endometrial cancer: The elusive link. J. Nurse Midwifery, 1980, 25, 19-21
2. Liberman, U.A.; Hochberg, M.C.; Geusens, P.; Shah, A.; Lin, J.; Chattopadhyay, A.; Ross, P.D. Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials. Int. J. Clin. Pract., 2006, 60, 1394-1400.
3. Yoshida, H.; Teramoto, T.; Ikeda, K.; Yamori, Y. Glycitein effect on suppressing the proliferation and stimulating the differentiation of osteoblastic MC3T3-E1 cells. Biosci. Biotechnol. Biochem., 2001, 65, 1211-1213.
4. Lee, K.H.; Choi, E.M. Biochanin A stimulates osteoblastic differentiation and inhibits hydrogen peroxide-induced production of inflammatory mediators in MC3T3-E1 cells. Biol. Pharm. Bull., 2005, 28, 1948-1953.
5. Chang, H.; Jin, T.Y.; Jin, W.F.; Gu, S.Z.; Zhou, Y.F. Modulation of isoflavones on bone-nodule formation in rat calvaria osteoblasts in vitro. Biomed. Environ. Sci., 2003, 16, 83-89.
6. Gao, Y.H.; Yamaguchi, M. Anabolic effect of daidzein on cortical bone in tissue culture: Comparison with genistein effect. Mol. Cell Biochem., 1999, 194, 93-97.
7. Sugimoto, E.; Yamaguchi, M. Stimulatory effect of Daidzein in osteoblastic MC3T3-E1 cells. Biochem. Pharmacol., 2000, 59, 471-475.
8. Ge, Y.; Chen, D.; Xie, L.; Zhang, R. Enhancing effect of daidzein on the differentiation and mineralization in mouse osteoblast-like MC3T3-E1 cells. Yakugaku. Zasshi., 2006, 126, 651-656.
9. Jia, T.L.; Wang, H.Z.; Xie, L.P.; Wang, X.Y.; Zhang, R.Q. Daidzein enhances osteoblast growth that may be mediated by increased bone morphogenetic protein (BMP) production. Biochem. Pharmacol., 2003, 65, 709-715.
10. Kakai, Y.; Kawase, T.; Nakano, T.; Mikuni-Takagaki, Y.; Saito, S. Effect of ipriflavone and estrogen on the differentiation and proliferation of osteogenic cells. Calcif. Tissue Int., 1992, 51 Suppl 1, S11-15.
11. Hagiwara, H.; Naruse, M.; Adachi, C.; Inoue, A.; Hiruma, Y.; Otsuka, E.; Naruse, K.; Demura, H.; Hirose, S. Ipriflavone downregulates endothelin receptor levels during differentiation of rat calvarial osteoblast-like cells. J. Biochem. (Tokyo)., 1999, 126, 168-173
12. Notoya, K.; Yoshida, K.; Tsukuda, R.; Taketomi, S. Effect of ipriflavone on expression of markers characteristic of the osteoblast phenotype in rat bone marrow stromal cell culture. J. Bone Miner. Res., 1994, 9, 395-400.
13. Benvenuti, S.; Tanini, A.; Frediani, U.; Bianchi, S.; Masi, L.; Casano, R.; Bufalino, L.; Serio, M.; Brandi, M.L. Effects of ipriflavone and its metabolites on a clonal osteoblastic cell line. J. Bone Miner. Res., 1991, 6, 987-996.
14. Cheng, S.L.; Zhang, S.F.; Nelson, T.L.; Warlow, P.M.; Civitelli, R. Stimulation of human osteoblast differentiation and function by ipriflavone and its metabolites. Calcif. Tissue Int., 1994, 55, 356-362.
15. Gao, Y.H.; Yamaguchi, M. Inhibitory effect of genistein on osteo-clast-like cell formation in mouse marrow cultures. Biochem. Pharmacol., 1999, 58, 767-772.
16. Kajiya, H.; Okabe, K.; Okamoto, F.; Tsuzuki, T.; Soeda, H. Protein tyrosine kinase inhibitors increase cytosolic calcium and inhibit actin organization as resorbing activity in rat osteoclasts. J. Cell Physiol., 2000, 183, 83-90.
17. Rassi, C.M.; Lieberherr, M.; Chaumaz, G.; Pointillart, A.; Cournot, G. Down-regulation of osteoclast differentiation by daidzein via caspase 3. J. Bone Miner. Res., 2002, 17, 630-638
18. Gao, Y.H.; Yamaguchi, M. Suppressive effect of genistein on rat bone osteoclasts: Apoptosis is induced through Ca2+ signaling. Biol. Pharm. Bull., 1999, 22, 805-809.
19. Blair, H.C.; Jordan, S.E.; Peterson, T.G.; Barnes, S. Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovariectomized rats. J. Cell Biochem., 1996, 61, 629-637.
20. Williams, J.P.; Jordan, S.E.; Barnes, S.; Blair, H.C. Tyrosine kinase inhibitor effects on avian osteoclastic acid transport. Am. J. Clin. Nutr., 1998, 68, 1369S-1374S.
21. Gao, Y.H.; Yamaguchi, M. Suppressive effect of genistein on rat bone osteoclasts: Involvement of protein kinase inhibition and protein tyrosine phosphatase activation. Int J. Mol. Med., 2000, 5, 261-267.
22. Okamoto, F.; Okabe, K.; Kajiya, H. Genistein, a soybean isoflavone, inhibits inward rectifier K(+) channels in rat osteoclasts. Jpn. J. Physiol., 2001, 51, 501-509.
23. Morita, I.; Sakaguchi, K.; Kurachi, T.; Murota, S. Ipriflavone inhibits murine osteoclast formation in vitro. Calcif. Tissue Int., 1992, 51 Suppl 1, S7-10.
24. Li, X.H.; Zhang, J.C.; Sui, S.F.; Yang, M.S. Effect of daidzin, genistin, and glycitin on osteogenic and adipogenic differentiation of bone marrow stromal cells and adipocytic transdifferentiation of osteoblasts. Acta Pharmacol. Sin., 2005, 26, 1081-1086.
25. Dang, Z.C.; Audinot, V.; Papapoulos, S.E.; Boutin, J.A.; Lowik, C.W. Peroxisome proliferator-activated receptor gamma (PPAR-gamma) as a molecular target for the soy phytoestrogen genistein. J. Biol. Chem., 2003, 278, 962-967.
26. Rayalam, S.; Della-Fera, M.A.; Ambati, S.; Yang, J.Y.; Park, H.J.; Baile, C.A. Enhanced effects of 1,25(OH)(2)D(3) plus genistein on adipogenesis and apoptosis in 3T3-L1 adipocytes. Obesity. (Silver Spring)., 2008, 16, 539-546.
27. Rayalam, S.; Della-Fera, M.A.; Yang, J.Y.; Park, H.J.; Ambati, S.; Baile, C.A. Resveratrol potentiates genistein's antiadipogenic and proapoptotic effects in 3T3-L1 adipocytes. J. Nutr., 2007, 137, 2668-2673.
28. Shen, P.; Liu, M.H.; Ng, T.Y.; Chan, Y.H.; Yong, E.L. Differential effects of isoflavones, from Astragalus membranaceus and Pueraria thomsonii, on the activation of PPARalpha, PPARgamma, and adipocyte differentiation in vitro. J. Nutr., 2006, 136, 899-905.
29. Ishimi, Y.; Yoshida, M.; Wakimoto, S.; Wu, J.; Chiba, H.; Wang, X.; Takeda, K.; Miyaura, C. Genistein, a soybean isoflavone, affects bone marrow lymphopoiesis and prevents bone loss in castrated male mice. Bone, 2002, 31, 180-185.
30. Wu, J.; Wang, X.X.; Chiba, H.; Higuchi, M.; Takasaki, M.; Ohta, A.; Ishimi, Y. Combined intervention of exercise and genistein prevented androgen deficiency-induced bone loss in mice. J. Appl. Physiol., 2003, 94, 335-342.
31. Khalil, D.A.; Lucas, E.A.; Smith, B.J.; Soung, D.Y.; Devareddy, L.; Juma, S.; Akhter, M.P.; Recker, R.; Arjmandi, B.H. Soy isoflavones may protect against orchidectomy-induced bone loss in aged male rats. Calcif. Tissue Int., 2005, 76, 56-62.
32. Soung, D.Y.; Devareddy, L.; Khalil, D.A.; Hooshmand, S.; Patade, A.; Lucas, E.A.; Arjmandi, B.H. Soy affects trabecular microarchitecture and favorably alters select bone-specific gene expressions in a male rat model of osteoporosis. Calcif. Tissue Int., 2006, 78, 385-391.
33. Li, B.; Yu, S. Genistein prevents bone resorption diseases by inhibiting bone resorption and stimulating bone formation. Biol. Pharm. Bull., 2003, 26, 780-786.
34. Anderson, J.J.; Ambrose, W.W.; Garner, S.C. Biphasic effects of genistein on bone tissue in the ovariectomized, lactating rat model. Proc. Soc. Exp. Biol. Med., 1998, 217, 345-350.
35. Somjen, D.; Katzburg, S.; Kohen, F.; Gayer, B.; Livne, E. Daidzein but not other phytoestrogens preserves bone architecture in ovariectomized female rats in vivo. J. Cell Biochem., 2008, 103, 1826-1832.
36. Om, A.S.; Shim, J.Y. Effect of daidzein, a soy isoflavone, on bone metabolism in Cd-treated ovariectomized rats. Acta Biochim. Pol., 2007, 54, 641-646.
37. Fonseca, D.; Ward, W.E. Daidzein together with high calcium preserve bone mass and biomechanical strength at multiple sites in ovariectomized mice. Bone, 2004, 35, 489-497.
38. Picherit, C.; Coxam, V.; Bennetau-Pelissero, C.; Kati-Coulibaly, S.; Davicco, M.J.; Lebecque, P.; Barlet, J.P. Daidzein is more efficient than genistein in preventing ovariectomy-induced bone loss in rats. J. Nutr., 2000, 130, 1675-1681.
39. Cecchini, M.G.; Fleisch, H.; Muhibauer, R.C. Ipriflavone inhibits bone resorption in intact and ovariectomized rats. Calcif. Tissue Int., 1997, 61 Suppl 1, S9-11.
40. Arjmandi, B.H.; Birnbaum, R.S.; Juma, S.; Barengolts, E.; Kukreja, S.C. The synthetic phytoestrogen, ipriflavone, and estrogen prevent bone loss by different mechanisms. Calcif. Tissue Int., 2000, 66, 61-65.
41. Deyhim, F.; Smith, B.J.; Soung, D.Y.; Juma, S.; Devareddy, L.; Arjmandi, B.H. Ipriflavone modulates IGF-I but is unable to restore bone in rats. Phytother. Res., 2005, 19, 116-120.
42. Civitelli, R. In vitro and in vivo effects of ipriflavone on bone formation and bone biomechanics. Calcif. Tissue Int., 1997, 61 Suppl 1, S12-14.
43. Ghezzo, C.; Civitelli, R.; Cadel, S.; Borelli, G.; Maiorino, M.; Bufalino, L.; Bongrani, S. Ipriflavone does not alter bone apatite crystal structure in adult male rats. Calcif. Tissue Int., 1996, 59, 496-499.
44. Civitelli, R.; Abbasi-Jarhomi, S.H.; Halstead, L.R.; Dimarogonas, A. Ipriflavone improves bone density and biomechanical properties of adult male rat bones. Calcif. Tissue Int., 1995, 56, 215-219.
45. Register, T.C.; Jayo, M.J.; Anthony, M.S. Soy phytoestrogens do not prevent bone loss in postmenopausal monkeys. J. Clin. Endocrinol. Metab., 2003, 88, 4362-4370.
46. De Wilde, A.; Maria Rassi, C.; Cournot, G.; Colin, C.; Lacroix, H.C.; Chaumaz, G.; Coxam, V.; Bennetau-Pelissero, C.; Pointillart, A.; Lieberherr, M. Dietary isoflavones act on bone marrow osteoprogenitor cells and stimulate ovary development before influencing bone mass in pre-pubertal piglets. J. Cell. Physiol., 2007, 212, 51-59.
47. Somekawa, Y.; Chiguchi, M.; Ishibashi, T.; Aso, T. Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. Obstet. Gynecol., 2001, 97, 109-115.
48. Mei, J.; Yeung, S.S.; Kung, A.W. High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women. J. Clin. Endocrinol. Metab., 2001, 86, 5217-5221.
49. Kritz-Silverstein, D.; Goodman-Gruen, D.L. Usual dietary isoflavone intake, bone mineral density, and bone metabolism in post-menopausal women. J. Womens. Health Gend. Based. Med., 2002, 11, 69-78.
50. Wangen, K.E.; Duncan, A.M.; Merz-Demlow, B.E.; Xu, X.; Marcus, R.; Phipps, W.R.; Kurzer, M.S. Effects of soy isoflavones on markers of bone turnover in premenopausal and postmenopausal women. J. Clin. Endocrinol. Metab., 2000, 85, 3043-3048.
51. Scheiber, M.D.; Liu, J.H.; Subbiah, M.T.; Rebar, R.W.; Setchell, K.D. Dietary inclusion of whole soy foods results in significant reductions in clinical risk factors for osteoporosis and cardiovascular disease in normal postmenopausal women. Menopause, 2001, 8, 384-392.
52. Morabito, N.; Crisafulli, A.; Vergara, C.; Gaudio, A.; Lasco, A.; Frisina, N.; D'Anna, R.; Corrado, F.; Pizzoleo, M.A.; Cincotta, M.; Altavilla, D.; Ientile, R.; Squadrito, F. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J. Bone Miner. Res., 2002, 17, 1904-1912.
53. Uesugi, T.; Fukui, Y.; Yamori, Y. Beneficial effects of soybean isoflavone supplementation on bone metabolism and serum lipids in postmenopausal japanese women: A four-week study. J. Am. Coll. Nutr., 2002, 21, 97-102.
54. Nikander, E.; Metsa-Heikkila, M.; Ylikorkala, O.; Tiitinen, A. Effects of phytoestrogens on bone turnover in postmenopausal women with a history of breast cancer. J. Clin. Endocrinol. Metab., 2004, 89, 1207-1212.
55. Chiechi, L.M.; Secreto, G.; D'Amore, M.; Fanelli, M.; Venturelli, E.; Cantatore, F.; Valerio, T.; Laselva, G.; Loizzi, P. Efficacy of a soy rich diet in preventing postmenopausal osteoporosis: The Menfis randomized trial. Maturitas, 2002, 42, 295-300
56. Arjmandi, B.H.; Lucas, E.A.; Khalil, D.A.; Devareddy, L.; Smith, B.J.; McDonald, J.; Arquitt, A.B.; Payton, M.E.; Mason, C. One year soy protein supplementation has positive effects on bone formation markers but not bone density in postmenopausal women. Nutr. J., 2005, 4, 8.
57. Potter, S.M.; Baum, J.A.; Teng, H.; Stillman, R.J.; Shay, N.F.; Erdman, J.W., Jr. Soy protein and isoflavones: Their effects on blood lipids and bone density in postmenopausal women. Am. J. Clin. Nutr., 1998, 68, 1375S-1379S.
58. Alekel, D.L.; Germain, A.S.; Peterson, C.T.; Hanson, K.B.; Stewart, J.W.; Toda, T. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J. Clin. Nutr., 2000, 72, 844-852.
59. Atkinson, C.; Compston, J.E.; Day, N.E.; Dowsett, M.; Bingham, S.A. The effects of phytoestrogen isoflavones on bone density in women: A double-blind, randomized, placebo-controlled trial. Am. J. Clin. Nutr., 2004, 79, 326-333.
60. Kreijkamp-Kaspers, S.; Kok, L.; Grobbee, D.E.; de Haan, E.H.; Aleman, A.; Lampe, J.W.; van der Schouw, Y.T. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: A randomized controlled trial. J. Am. Med. Assoc., 2004, 292, 65-74.
61. Lydeking-Olsen, E.; Beck-Jensen, J.E.; Setchell, K.D.; Holm-Jensen, T. Soymilk or progesterone for prevention of bone loss - a 2 year randomized, placebo-controlled trial. Eur. J. Nutr., 2004, 43, 246-257.
62. Melis, G.B.; Paoletti, A.M.; Bartolini, R.; Tosti Balducci, M.; Massi, G.B.; Bruni, V.; Becorpi, A.; Ottanelli, S.; Fioretti, P.; Gambacciani, M.; et al. Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium. Bone. Miner., 1992, 19 Suppl 1, S49-56.
63. Alexandersen, P.; Toussaint, A.; Christiansen, C.; Devogelaer, J.P.; Roux, C.; Fechtenbaum, J.; Gennari, C.; Reginster, J.Y. Ipriflavone in the treatment of postmenopausal osteoporosis: A randomized controlled trial. J. Am. Med. Assoc., 2001, 285, 1482-1488
64. Agnusdei, D.; Crepaldi, G.; Isaia, G.; Mazzuoli, G.; Ortolani, S.; Passeri, M.; Bufalino, L.; Gennari, C. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss. Calcif. Tissue Int., 1997, 61, 142-147.
65. Adami, S.; Bufalino, L.; Cervetti, R.; Di Marco, C.; Di Munno, O.; Fantasia, L.; Isaia, G.C.; Serni, U.; Vecchiet, L.; Passeri, M. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years. Osteoporos. Int., 1997, 7, 119-125.
66. Gennari, C.; Agnusdei, D.; Crepaldi, G.; Isaia, G.; Mazzuoli, G.; Ortolani, S.; Bufalino, L.; Passeri, M. Effect of ipriflavone - a synthetic derivative of natural isoflavones - on bone mass loss in the early years after menopause. Menopause, 1998, 5, 9-15.
67. Halpner, A.D.; Kellermann, G.; Ahlgrimm, M.J.; Arndt, C.L.; Shaikh, N.A.; Hargrave, J.J.; Tallas, P.G. The effect of an ipriflavone-containing supplement on urinary N-linked telopeptide levels in postmenopausal women. J. Womens Health Gend. Based Med., 2000, 9, 995-998.
68. Katase, K.; Kato, T.; Hirai, Y.; Hasumi, K.; Chen, J.T. Effects of ipriflavone on bone loss following a bilateral ovariectomy and menopause: A randomized placebo-controlled study. Calcif. Tissue Int., 2001, 69, 73-77.
69. Marini, H.; Minutoli, L.; Polito, F.; Bitto, A.; Altavilla, D.; Atteritano, M.; Gaudio, A.; Mazzaferro, S.; Frisina, A.; Frisina, N.; Lubrano, C.; Bonaiuto, M.; D'Anna, R.; Cannata, M.L.; Corrado, F.; Adamo, E.B.; Wilson, S.; Squadrito, F. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: A randomized trial. Ann. Intern. Med., 2007, 146, 839-847.
70. Yang, Y.J.; Yang, Z.L.; Wang, D.C.; Xiao, X.C.; Li, P. [Comparative study on effects of rutin and quercetin on metabolism in osteoblast cells]. Zhong. Yao. Cai., 2006, 29, 467-470.
71. Miyake, M.; Arai, N.; Ushio, S.; Iwaki, K.; Ikeda, M.; Kurimoto, M. Promoting effect of kaempferol on the differentiation and mineralization of murine pre-osteoblastic cell line MC3T3-E1. Biosci. Biotechnol. Biochem., 2003, 67, 1199-1205.
72. Trivedi, R.; Kumar, S.; Kumar, A.; Siddiqui, J.A.; Swarnkar, G.; Gupta, V.; Kendurker, A.; Dwivedi, A.K.; Romero, J.R.; Chattopadhyay, N. Kaempferol has osteogenic effect in ovariectomized adult Sprague-Dawley rats. Mol. Cell. Endocrinol., 2008.
73. Prouillet, C.; Maziere, J.C.; Maziere, C.; Wattel, A.; Brazier, M.; Kamel, S. Stimulatory effect of naturally occurring flavonols quercetin and kaempferol on alkaline phosphatase activity in MG-63 human osteoblasts through ERK and estrogen receptor pathway. Biochem. Pharmacol., 2004, 67, 1307-1313.
74. Yin, X.X.; Chen, Z.Q.; Liu, Z.J.; Ma, Q.J.; Dang, G.T. Icariine stimulates proliferation and differentiation of human osteoblasts by increasing production of bone morphogenetic protein 2. Chin. Med. J. (Engl)., 2007, 120, 204-210.
75. Chen, K.M.; Ge, B.F.; Ma, H.P.; Liu, X.Y.; Bai, M.H.; Wang, Y. Icariin, a flavonoid from the herb Epimedium enhances the osteogenic differentiation of rat primary bone marrow stromal cells. Pharmazie., 2005, 60, 939-942.
76. Chen, K.M.; Ma, H.P.; Ge, B.F.; Liu, X.Y.; Ma, L.P.; Bai, M.H.; Wang, Y. Icariin enhances the osteogenic differentiation of bone marrow stromal cells but has no effects on the differentiation of newborn calvarial osteoblasts of rats. Pharmazie, 2007, 62, 785-789
77. Yin, X.X.; Chen, Z.Q.; Dang, G.T.; Ma, Q.J.; Liu, Z.J. [Effects of Epimedium pubescens icariine on proliferation and differentiation of human osteoblasts]. Zhongguo. Zhong. Yao. Za. Zhi., 2005, 30, 289-291.
78. Hsu, Y.L.; Chang, J.K.; Tsai, C.H.; Chien, T.T.; Kuo, P.L. Myricetin induces human osteoblast differentiation through bone morphogenetic protein-2/p38 mitogen-activated protein kinase pathway. Biochem. Pharmacol., 2007, 73, 504-514.
79. Kuo, P.L. Myricetin inhibits the induction of anti-Fas IgM-, tumor necrosis factor-alpha- and interleukin-1beta-mediated apoptosis by Fas pathway inhibition in human osteoblastic cell line MG-63. Life Sci., 2005, 77, 2964-2976.
80. Pang, J.L.; Ricupero, D.A.; Huang, S.; Fatma, N.; Singh, D.P.; Romero, J.R.; Chattopadhyay, N. Differential activity of kaempferol and quercetin in attenuating tumor necrosis factor receptor family signaling in bone cells. Biochem. Pharmacol., 2006, 71, 818-826.
81. Vali, B.; Rao, L.G.; El-Sohemy, A. Epigallocatechin-3-gallate increases the formation of mineralized bone nodules by human osteoblast-like cells. J. Nutr. Biochem., 2007, 18, 341-347.
82. Yun, J.H.; Pang, E.K.; Kim, C.S.; Yoo, Y.J.; Cho, K.S.; Chai, J.K.; Kim, C.K.; Choi, S.H. Inhibitory effects of green tea polyphenol (-)-epigallocatechin gallate on the expression of matrix metalloproteinase-9 and on the formation of osteoclasts. J. Periodontal. Res., 2004, 39, 300-307.
83. Yamauchi, J.; Takai, S.; Matsushima-Nishiwaki, R.; Hanai, Y.; Doi, T.; Kato, H.; Ogura, S.; Kato, K.; Tokuda, H.; Kozawa, O. (-)-epigallocatechin gallate inhibits prostaglandin D2-stimulated HSP27 induction via suppression of the p44/p42 MAP kinase pathway in osteoblasts. Prostaglandins Leukot. Essent. Fatty Acids., 2007, 77, 173-179.
84. Wu, J.B.; Fong, Y.C.; Tsai, H.Y.; Chen, Y.F.; Tsuzuki, M.; Tang, C.H. Naringin-induced bone morphogenetic protein-2 expression via PI3K, Akt, c-Fos/c-Jun and AP-1 pathway in osteoblasts. Eur. J. Pharmacol., 2008, 588, 333-341.
85. Wong, R.W.; Rabie, A.B. Effect of naringin on bone cells. J. Orthop. Res., 2006, 24, 2045-2050.
86. Choi, E.H.; Ok, H.E.; Yoon, Y.; Magnuson, B.A.; Kim, M.K.; Chun, H.S. Protective effect of anthocyanin-rich extract from bilberry (Vaccinium myrtillus L.) against myelotoxicity induced by 5-fluorouracil. Biofactors, 2007, 29, 55-65.
87. Choi, E.M. Apigenin increases osteoblastic differentiation and inhibits tumor necrosis factor-alpha-induced production of interleukin-6 and nitric oxide in osteoblastic MC3T3-E1 cells. Pharmazie, 2007, 62, 216-220.
88. Bandyopadhyay, S.; Lion, J.M.; Mentaverri, R.; Ricupero, D.A.; Kamel, S.; Romero, J.R.; Chattopadhyay, N. Attenuation of osteoclastogenesis and osteoclast function by apigenin. Biochem. Pharmacol., 2006,72, 184-197.
89. Wattel, A.; Kamel, S.; Mentaverri, R.; Lorget, F.; Prouillet, C.; Petit, J.P.; Fardelonne, P.; Brazier, M. Potent inhibitory effect of naturally occurring flavonoids quercetin and kaempferol on in vitro osteoclastic bone resorption. Biochem. Pharmacol., 2003, 65, 35-42.
90. Wattel, A.; Kamel, S.; Prouillet, C.; Petit, J.P.; Lorget, F.; Offord, E.; Brazier, M. Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF kappa B and AP-1. J. Cell. Biochem., 2004, 92, 285-295.
91. Bax, B.E.; Alam, A.S.; Banerji, B.; Bax, C.M.; Bevis, P.J.; Stevens, C.R.; Moonga, B.S.; Blake, D.R.; Zaidi, M. Stimulation of osteoclastic bone resorption by hydrogen peroxide. Biochem. Biophys. Res. Commun., 1992, 183, 1153-1158.
92. Kozlov, A.B.; Ostrachovitch, E.A.; Afanas'ev, I.B. Mechanism of inhibitory effects of chelating drugs on lipid peroxidation in rat brain homogenates. Biochem. Pharmacol., 1994, 47, 795-799.
93. Afanas'ev, I.B.; Ostrachovitch, E.A.; Abramova, N.E.; Korkina, L.G. Different antioxidant activities of bioflavonoid rutin in normal and iron-overloading rats. Biochem. Pharmacol., 1995, 50, 627-635.
94. Rassi, C.M.; Lieberherr, M.; Chaumaz, G.; Pointillart, A.; Cournot, G. Modulation of osteoclastogenesis in porcine bone marrow cultures by quercetin and rutin. Cell Tissue Res., 2005, 319, 383-393.
95. Yamaguchi, M.; Hamamoto, R.; Uchiyama, S.; Ishiyama, K. Effects of flavonoid on calcium content in femoral tissue culture and parathyroid hormone-stimulated osteoclastogenesis in bone marrow culture in vitro. Mol. Cell Biochem., 2007, 303, 83-88.
96. Chen, K.M.; Ge, B.F.; Liu, X.Y.; Ma, P.H.; Lu, M.B.; Bai, M.H.; Wang, Y. Icariin inhibits the osteoclast formation induced by RANKL and macrophage-colony stimulating factor in mouse bone marrow culture. Pharmazie, 2007, 62, 388-391.
97. Huang, J.; Yuan, L.; Wang, X.; Zhang, T.L.; Wang, K. Icaritin and its glycosides enhance osteoblastic, but suppress osteoclastic, differentiation and activity in vitro. Life Sci., 2007, 81, 832-840.
98. Delaisse, J.M.; Eeckhout, Y.; Vaes, G. Inhibition of bone resorption in culture by (+)-catechin. Biochem. Pharmacol., 1986, 35, 3091-3094.
99. Nakagawa, H.; Wachi, M.; Woo, J.T.; Kato, M.; Kasai, S.; Takahashi, F.; Lee, I.S.; Nagai, K. Fenton reaction is primarily involved in a mechanism of (-)-epigallocatechin-3-gallate to induce osteoclastic cell death. Biochem. Biophys. Res. Commun., 2002, 292, 94-101.
100. Hsu, C.L.; Yen, G.C. Induction of cell apoptosis in 3T3-L1 preadipocytes by flavonoids is associated with their antioxidant activity. Mol. Nutr. Food Res., 2006, 50, 1072-1079.
101. Yang, J.Y.; Della-Fera, M.A.; Rayalam, S.; Ambati, S.; Hartzell, D.L.; Park, H.J.; Baile, C.A. Enhanced inhibition of adipogenesis and induction of apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetin. Life Sci., 2008, 82, 1032-1039.
102. Trivedi, R.; Kumar, S.; Kumar, A.; Siddiqui, J.A.; Swarnkar, G.; Gupta, V.; Kendurker, A.; Dwivedi, A.K.; Romero, J.R.; Chattopadhyay, N. Kaempferol has osteogenic effect in ovariectomized adult Sprague-Dawley rats. Mol. Cell Endocrinol., 2008, 289, 85-93.
103. Hsu, C.L.; Yen, G.C. Effects of flavonoids and phenolic acids on the inhibition of adipogenesis in 3T3-L1 adipocytes. J. Agric. Food Chem., 2007, 55, 8404-8410.
104. Choi, I.; Park, Y.; Choi, H.; Lee, E.H. Anti-adipogenic activity of rutin in 3T3-L1 cells and mice fed with high-fat diet. Biofactors, 2006, 26, 273-281.
105. Morikawa, K.; Ikeda, C.; Nonaka, M.; Pei, S.; Mochizuki, M.; Mori, A.; Yamada, S. Epigallocatechin gallate-induced apoptosis does not affect adipocyte conversion of preadipocytes. Cell Biol. Int., 2007, 31, 1379-1387.
106. Moon, H.S.; Chung, C.S.; Lee, H.G.; Kim, T.G.; Choi, Y.J.; Cho, C.S. Inhibitory effect of (-)-epigallocatechin-3-gallate on lipid accumulation of 3T3-L1 cells. Obesity (Silver Spring)., 2007, 15, 2571-2582.
107. Hwang, J.T.; Park, I.J.; Shin, J.I.; Lee, Y.K.; Lee, S.K.; Baik, H.W.; Ha, J.; Park, O.J. Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process via activating AMP-activated protein kinase. Biochem. Biophys. Res. Commun., 2005, 338, 694-699
108. Nelson-Dooley, C.; Della-Fera, M.A.; Hamrick, M.; Baile, C.A. Novel treatments for obesity and osteoporosis: Targeting apoptotic pathways in adipocytes. Curr. Med. Chem., 2005, 12, 2215-2225
109. Bao, J.R.; Yang, J.W.; Li, S.F.; Zhao, W.; Zhang, Q.; Yan, Y. [Effects of Icariin on ovariectomized osteoporotic rats]. Wei. Sheng. Yan. Jiu., 2005, 34, 191-193.
110. Horcajada-Molteni, M.N.; Crespy, V.; Coxam, V.; Davicco, M.J.; Remesy, C.; Barlet, J.P. Rutin inhibits ovariectomy-induced osteopenia in rats. J. Bone Miner. Res., 2000, 15, 2251-2258.
111. Kanter, M.; Altan, M.F.; Donmez, S.; Ocakci, A.; Kartal, M.E. The effects of quercetin on bone minerals, biomechanical behavior, and structure in streptozotocin-induced diabetic rats. Cell. Biochem. Funct., 2007, 25, 747-752.
112. Wong, R.W.; Rabie, A.B. Effect of quercetin on bone formation. J. Orthop. Res., 2008.
113. Wong, R.W.; Rabie, A.B. Effect of naringin collagen graft on bone formation. Biomaterials, 2006, 27, 1824-1831.
114. Wei, M.; Yang, Z.; Li, P.; Zhang, Y.; Sse, W.C. Anti-osteoporosis activity of naringin in the retinoic acid-induced osteoporosis model. Am. J. Chin. Med., 2007, 35, 663-667.
115. Chiba, H.; Uehara, M.; Wu, J.; Wang, X.; Masuyama, R.; Suzuki, K.; Kanazawa, K.; Ishimi, Y. Hesperidin, a citrus flavonoid, inhibits bone loss and decreases serum and hepatic lipids in ovariectomized mice. J. Nutr., 2003, 133, 1892-1897.
116. Horcajada, M.N.; Habauzit, V.; Trzeciakiewicz, A.; Morand, C.; Gil-Izquierdo, A.; Mardon, J.; Lebecque, P.; Davicco, M.J.; Chee, W.S.; Coxam, V.; Offord, E. Hesperidin inhibits ovariectomized-induced osteopenia and shows differential effects on bone mass and strength in young and adult intact rats. J. Appl. Physiol., 2008, 104, 648-654.
117. Park, J.A.; Ha, S.K.; Kang, T.H.; Oh, M.S.; Cho, M.H.; Lee, S.Y.; Park, J.H.; Kim, S.Y. Protective effect of apigenin on ovariectomy-induced bone loss in rats. Life Sci., 2008, 82, 1217-1223
118. Mizutani, K.; Ikeda, K.; Kawai, Y.; Yamori, Y. Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Biochem. Biophys. Res. Commun., 1998, 253, 859-863
119. Dai, Z.; Li, Y.; Quarles, L.D.; Song, T.; Pan, W.; Zhou, H.; Xiao, Z. Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine, 2007, 14, 806-814.
120. Song, L.H.; Pan, W.; Yu, Y.H.; Quarles, L.D.; Zhou, H.H.; Xiao, Z.S. Resveratrol prevents CsA inhibition of proliferation and osteoblastic differentiation of mouse bone marrow-derived mesenchymal stem cells through an ER/NO/cGMP pathway. Toxicol. In Vitro, 2006, 20, 915-922.
121. Kanno, S.; Hirano, S.; Kayama, F. Effects of phytoestrogens and environmental estrogens on osteoblastic differentiation in MC3T3-E1 cells. Toxicology, 2004, 196, 137-145.
122. Lee, J.A.; Hwang, J.A.; Sung, H.N.; Jeon, C.H.; Gill, B.C.; Youn, H.J.; Park, J.H. 2,3,7,8-Tetrachlorodibenzo-p-dioxin modulates functional differentiation of mouse bone marrow-derived dendritic cells Downregulation of RelB by 2,3,7,8-tetrachlorodibenzo-pdioxin. Toxicol. Lett., 2007, 173, 31-40.
123. Yang, X.J.; Wong, M.S.; Wang, N.L.; Chan, S.C.; Yao, X.S. Lignans from the stems of Sambucus williamsii and their effects on osteoblastic UMR106 cells. J. Asian. Nat. Prod. Res., 2007, 9, 583-591.
124. Lees, C.J.; Kaplan, J.R.; Chen, H.; Jerome, C.P.; Register, T.C.; Franke, A.A. Bone mass and soy isoflavones in socially housed, premenopausal macaques. Am. J. Clin. Nutr., 2007, 86, 245-250.
125. Boissy, P.; Andersen, T.L.; Abdallah, B.M.; Kassem, M.; Plesner, T.; Delaisse, J.M. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res., 2005, 65, 9943-9952.
126. Saftig, P.; Hunziker, E.; Wehmeyer, O.; Jones, S.; Boyde, A.; Rommerskirch, W.; Moritz, J.D.; Schu, P.; von Figura, K. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. USA, 1998, 95, 13453-13458.
127. Matsuo, K.; Galson, D.L.; Zhao, C.; Peng, L.; Laplace, C.; Wang, K.Z.; Bachler, M.A.; Amano, H.; Aburatani, H.; Ishikawa, H.; Wagner, E.F. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J. Biol. Chem., 2004, 279, 26475-26480.
128. Pervaiz, S. Resveratrol: From grapevines to mammalian biology. FASEB J., 2003, 17, 1975-1985.
129. Kanno, S.; Hirano, S.; Kayama, F. Effects of the phytoestrogen coumestrol on RANK-ligand-induced differentiation of osteoclasts. Toxicology, 2004, 203, 211-220.
130. Park, E.K.; Kim, M.S.; Lee, S.H.; Kim, K.H.; Park, J.Y.; Kim, T.H.; Lee, I.S.; Woo, J.T.; Jung, J.C.; Shin, H.I.; Choi, J.Y.; Kim, S.Y. Furosin, an ellagitannin, suppresses RANKL-induced osteoclast differentiation and function through inhibition of MAP kinase activation and actin ring formation. Biochem. Biophys. Res. Commun., 2004, 325, 1472-1480.
131. Kim, S.H.; Park, H.S.; Lee, M.S.; Cho, Y.J.; Kim, Y.S.; Hwang, J.T.; Sung, M.J.; Kim, M.S.; Kwon, D.Y. Vitisin A inhibits adipocyte differentiation through cell cycle arrest in 3T3-L1 cells. Biochem. Biophys. Res. Commun., 2008, 372, 108-113
132. Madsen, L.; Petersen, R.K.; Sorensen, M.B.; Jorgensen, C.; Hallenborg, P.; Pridal, L.; Fleckner, J.; Amri, E.Z.; Krieg, P.; Furstenberger, G.; Berge, R.K.; Kristiansen, K. Adipocyte differentiation of 3T3-L1 preadipocytes is dependent on lipoxygenase activity during the initial stages of the differentiation process. Biochem. J., 2003, 375, 539-549.
133. Liu, Z.P.; Li, W.X.; Yu, B.; Huang, J.; Sun, J.; Huo, J.S.; Liu, C.X. Effects of trans-resveratrol from Polygonum cuspidatum on bone loss using the ovariectomized rat model. J. Med. Food, 2005, 8, 14-19.
134. Draper, C.R.; Edel, M.J.; Dick, I.M.; Randall, A.G.; Martin, G.B.; Prince, R.L. Phytoestrogens reduce bone loss and bone resorption in oophorectomized rats. J. Nutr., 1997, 127, 1795-1799.
135. Yin, J.; Tezuka, Y.; Subehan; Shi, L.; Nobukawa, M.; Nobukawa, T.; Kadota, S. In vivo anti-osteoporotic activity of isotaxiresinol, a lignan from wood of Taxus yunnanensis. Phytomedicine, 2006, 13, 37-42.
136. Yamaguchi, M.; Uchiyama, S. Effect of carotenoid on calcium content and alkaline phosphatase activity in rat femoral tissues in vitro: The unique anabolic effect of beta-cryptoxanthin. Biol. Pharm. Bull., 2003, 26, 1188-1191.
137. Yamaguchi, M.; Uchiyama, S. beta-Cryptoxanthin stimulates bone formation and inhibits bone resorption in tissue culture in vitro. Mol. Cell Biochem., 2004, 258, 137-144.
138. Kim, L.; Rao, A.V.; Rao, L.G. Lycopene II- effect on osteoblasts: The carotenoid lycopene stimulates cell proliferation and alkaline phosphatase activity of SaOS-2 cells. J. Med. Food, 2003, 6, 79-86.
139. Uchiyama, S.; Yamaguchi, M. beta-cryptoxanthin stimulates cell differentiation and mineralization in osteoblastic MC3T3-E1 cells. J. Cell Biochem., 2005, 95, 1224-1234.
140. Uchiyama, S.; Yamaguchi, M. beta-Cryptoxanthin stimulates cell proliferation and transcriptional activity in osteoblastic MC3T3-E1 cells. Int. J. Mol. Med., 2005, 15, 675-681.
141. Song, H.M.; Nacamuli, R.P.; Xia, W.; Bari, A.S.; Shi, Y.Y.; Fang, T.D.; Longaker, M.T. High-dose retinoic acid modulates rat calvarial osteoblast biology. J. Cell. Physiol., 2005, 202, 255-262.
142. Nagasawa, H.; Takahashi, S.; Kobayashi, A.; Tazawa, H.; Tashima, Y.; Sato, K. Effect of retinoic acid on murine preosteoblastic MC3T3-E1 cells. J. Nutr. Sci. Vitaminol. (Tokyo)., 2005, 51, 311-318.
143. Park, C.K.; Ishimi, Y.; Ohmura, M.; Yamaguchi, M.; Ikegami, S. Vitamin A and carotenoids stimulate differentiation of mouse osteoblastic cells. J. Nutr. Sci. Vitaminol. (Tokyo)., 1997, 43, 281-296.
144. Uchiyama, S.; Yamaguchi, M. Inhibitory effect of betacryptoxanthin on osteoclast-like cell formation in mouse marrow cultures. Biochem. Pharmacol., 2004, 67, 1297-1305.
145. Uchiyama, S.; Yamaguchi, M. Beta-cryptoxanthin stimulates apoptotic cell death and suppresses cell function in osteoclastic cells: Change in their related gene expression. J. Cell. Biochem., 2006, 98, 1185-1195.
146. Rao, L.G.; Krishnadev, N.; Banasikowska, K.; Rao, A.V. Lycopene I- effect on osteoclasts: Lycopene inhibits basal and parathyroid hormone-stimulated osteoclast formation and mineral resorption mediated by reactive oxygen species in rat bone marrow cultures. J. Med. Food, 2003, 6, 69-78.
147. Scheven, B.A.; Hamilton, N.J. Retinoic acid and 1,25-dihydroxyvitamin D3 stimulate osteoclast formation by different mechanisms. Bone., 1990, 11, 53-59.
148. Saneshige, S.; Mano, H.; Tezuka, K.; Kakudo, S.; Mori, Y.; Honda, Y.; Itabashi, A.; Yamada, T.; Miyata, K.; Hakeda, Y.; et al. Retinoic acid directly stimulates osteoclastic bone resorption and gene expression of cathepsin K/OC-2. Biochem. J., 1995, 309 ( Pt 3), 721-724.
149. Kaji, H.; Sugimoto, T.; Kanatani, M.; Fukase, M.; Kumegawa, M.; Chihara, K. Retinoic acid induces osteoclast-like cell formation by directly acting on hemopoietic blast cells and stimulates osteopontin mRNA expression in isolated osteoclasts. Life Sci., 1995, 56, 1903-1913.
150. Uchiyama, S.; Sumida, T.; Yamaguchi, M. Oral administration of beta-cryptoxanthin induces anabolic effects on bone components in the femoral tissues of rats in vivo. Biol. Pharm. Bull., 2004, 27, 232-235.
151. Uchiyama, S.; Yamaguchi, M. Oral administration of betacryptoxanthin prevents bone loss in ovariectomized rats. Int. J. Mol. Med., 2006, 17, 15-20.
152. Kneissel, M.; Studer, A.; Cortesi, R.; Susa, M. Retinoid-induced bone thinning is caused by subperiosteal osteoclast activity in adult rodents. Bone, 2005, 36, 202-214.
153. Coward, L.; Smith, M.; Kirk, M.; Barnes, S. Chemical modification of isoflavones in soyfoods during cooking and processing. Am. J. Clin. Nutr., 1998, 68, 1486S-1491S.
154. Setchell, K.D.; Brown, N.M.; Desai, P.; Zimmer-Nechemias, L.; Wolfe, B.E.; Brashear, W.T.; Kirschner, A.S.; Cassidy, A.; Heubi, J.E. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J. Nutr., 2001, 131, 1362S-1375S.
155. Izumi, T.; Piskula, M.K.; Osawa, S.; Obata, A.; Tobe, K.; Saito, M.; Kataoka, S.; Kubota, Y.; Kikuchi, M. Soy isoflavone aglycones are absorbed faster and in higher amounts than their glucosides in humans. J. Nutr., 2000, 130, 1695-1699.
156. Sfakianos, J.; Coward, L.; Kirk, M.; Barnes, S. Intestinal uptake and biliary excretion of the isoflavone genistein in rats. J. Nutr., 1997, 127, 1260-1268.
157. Setchell, K.D.; Faughnan, M.S.; Avades, T.; Zimmer-Nechemias, L.; Brown, N.M.; Wolfe, B.E.; Brashear, W.T.; Desai, P.; Oldfield, M.F.; Botting, N.P.; Cassidy, A. Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women. Am. J. Clin. Nutr., 2003, 77, 411-419.
158. Zhang, Y.; Wang, G.J.; Song, T.T.; Murphy, P.A.; Hendrich, S. Urinary disposition of the soybean isoflavones daidzein, genistein and glycitein differs among humans with moderate fecal isoflavone degradation activity. J. Nutr., 1999, 129, 957-962.
159. Bloedon, L.T.; Jeffcoat, A.R.; Lopaczynski, W.; Schell, M.J.; Black, T.M.; Dix, K.J.; Thomas, B.F.; Albright, C.; Busby, M.G.; Crowell, J.A.; Zeisel, S.H. Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women. Am. J. Clin. Nutr., 2002, 76, 1126-1137.
160. Setchell, K.D.; Brown, N.M.; Lydeking-Olsen, E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J. Nutr., 2002, 132, 3577-3584.
161. Zubik, L.; Meydani, M. Bioavailability of soybean isoflavones from aglycone and glucoside forms in American women. Am. J. Clin. Nutr., 2003, 77, 1459-1465.
162. Lu, L.J.; Lin, S.N.; Grady, J.J.; Nagamani, M.; Anderson, K.E. Altered kinetics and extent of urinary daidzein and genistein excretion in women during chronic soya exposure. Nutr. Cancer, 1996, 26, 289-302.
163. Lampe, J.W.; Skor, H.E.; Li, S.; Wahala, K.; Howald, W.N.; Chen, C. Wheat bran and soy protein feeding do not alter urinary excretion of the isoflavan equol in premenopausal women. J. Nutr., 2001, 131, 740-744.
164. Kim, S.H.; Lee, M.G. Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects. Life Sci., 2002, 70, 1299-1315.
165. Rohatagi, S.; Barrett, J.S.; Sawyers, W.; Yu, K.; Morales, R.J. Pharmacokinetics of ipriflavone and metabolites after oral administration of a corn-oil suspension relative to the Osteofix tablet. Am. J. Ther., 1997, 4, 229-238.
166. Noroozi, M.; Burns, J.; Crozier, A.; Kelly, I.E.; Lean, M.E. Prediction of dietary flavonol consumption from fasting plasma concentration or urinary excretion. Eur. J. Clin. Nutr., 2000, 54, 143-149.
167. Erlund, I.; Silaste, M.L.; Alfthan, G.; Rantala, M.; Kesaniemi, Y.A.; Aro, A. Plasma concentrations of the flavonoids hesperetin, naringenin and quercetin in human subjects following their habitual diets, and diets high or low in fruit and vegetables. Eur. J. Clin. Nutr., 2002, 56, 891-898.
168. Boyle, S.P.; Dobson, V.L.; Duthie, S.J.; Hinselwood, D.C.; Kyle, J.A.; Collins, A.R. Bioavailability and efficiency of rutin as an antioxidant: a human supplementation study. Eur. J. Clin. Nutr., 2000, 54, 774-782.
169. Conquer, J.A.; Maiani, G.; Azzini, E.; Raguzzini, A.; Holub, B.J. Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. J. Nutr., 1998, 128, 593-597.
170. Moon, J.H.; Nakata, R.; Oshima, S.; Inakuma, T.; Terao, J. Accumulation of quercetin conjugates in blood plasma after the short-term ingestion of onion by women. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2000, 279, R461-467.
171. Scalbert, A.; Williamson, G. Dietary intake and bioavailability of polyphenols. J. Nutr., 2000, 130, 2073S-2085S.
172. Manach, C.; Williamson, G.; Morand, C.; Scalbert, A.; Remesy, C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am. J. Clin. Nutr., 2005, 81, 230S-242S.
173. Gugler, R.; Leschik, M.; Dengler, H.J. Disposition of quercetin in man after single oral and intravenous doses. Eur. J. Clin. Pharmacol., 1975, 9, 229-234.
174. Hollman, P.C.; de Vries, J.H.; van Leeuwen, S.D.; Mengelers, M.J.; Katan, M.B. Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am. J. Clin. Nutr., 1995, 62, 1276-1282.
175. Day, A.J.; Mellon, F.; Barron, D.; Sarrazin, G.; Morgan, M.R.; Williamson, G. Human metabolism of dietary flavonoids: Identification of plasma metabolites of quercetin. Free Radic. Res., 2001, 35, 941-952.
176. Olthof, M.R.; Hollman, P.C.; Vree, T.B.; Katan, M.B. Bioavailabilities of quercetin-3-glucoside and quercetin-4'-glucoside do not differ in humans. J. Nutr., 2000, 130, 1200-1203.
177. Graefe, E.U.; Wittig, J.; Mueller, S.; Riethling, A.K.; Uehleke, B.; Drewelow, B.; Pforte, H.; Jacobasch, G.; Derendorf, H.; Veit, M. Pharmacokinetics and bioavailability of quercetin glycosides in humans. J. Clin. Pharmacol., 2001, 41, 492-499.
178. Scheline, R.R. CRC handbook of mammalian metabolism of plant compounds, CRC Press: Boca. Raton, FL.,1991.
179. Booth, A.N.; Deeds, F.; Jones, F.T.; Murray, C.W. The metabolic fate of rutin and quercetin in the animal body. J. Biol. Chem., 1956, 223, 251-257.
180. Baba, S.; Furuta, T.; Horie, M.; Nakagawa, H. Studies on drug metabolism by use of isotopes XXVI: Determination of urinary metabolites of rutin in humans. J. Pharm. Sci., 1981, 70, 780-782.
181. Aura, A.M.; O'Leary, K.A.; Williamson, G.; Ojala, M.; Bailey, M.; Puupponen-Pimia, R.; Nuutila, A.M.; Oksman-Caldentey, K.M.; Poutanen, K. Quercetin derivatives are deconjugated and converted to hydroxyphenylacetic acids but not methylated by human fecal flora in vitro. J. Agric. Food Chem., 2002, 50, 1725-1730.
182. Sawai, Y.; Kohsaka, K.; Nishiyama, Y.; Ando, K. Serum concentrations of rutoside metabolites after oral administration of a rutoside formulation to humans. Arzneimittelforschung., 1987, 37, 729-732.
183. Lee, M.J.; Maliakal, P.; Chen, L.; Meng, X.; Bondoc, F.Y.; Prabhu, S.; Lambert, G.; Mohr, S.; Yang, C.S. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: Formation of different metabolites and individual variability. Cancer Epidemiol. Biomarkers Prev., 2002, 11, 1025-1032.
184. Donovan, J.L.; Bell, J.R.; Kasim-Karakas, S.; German, J.B.; Walzem, R.L.; Hansen, R.J.; Waterhouse, A.L. Catechin is present as metabolites in human plasma after consumption of red wine. J. Nutr., 1999, 129, 1662-1668.
185. Holt, R.R.; Lazarus, S.A.; Sullards, M.C.; Zhu, Q.Y.; Schramm, D.D.; Hammerstone, J.F.; Fraga, C.G.; Schmitz, H.H.; Keen, C.L. Procyanidin dimer B2 [epicatechin-(4beta-8)-epicatechin] in human plasma after the consumption of a flavanol-rich cocoa. Am. J. Clin. Nutr., 2002, 76, 798-804.
186. Yang, C.S.; Chen, L.; Lee, M.J.; Balentine, D.; Kuo, M.C.; Schantz, S.P. Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol. Biomarkers Prev., 1998, 7, 351-354.
187. Bell, J.R.; Donovan, J.L.; Wong, R.; Waterhouse, A.L.; German, J.B.; Walzem, R.L.; Kasim-Karakas, S.E. (+)-Catechin in human plasma after ingestion of a single serving of reconstituted red wine. Am. J. Clin. Nutr., 2000, 71, 103-108.
188. Meng, X.; Sang, S.; Zhu, N.; Lu, H.; Sheng, S.; Lee, M.J.; Ho, C.T.; Yang, C.S. Identification and characterization of methylated and ring-fission metabolites of tea catechins formed in humans, mice, and rats. Chem. Res. Toxicol., 2002, 15, 1042-1050
189. Li, C.; Lee, M.J.; Sheng, S.; Meng, X.; Prabhu, S.; Winnik, B.; Huang, B.; Chung, J.Y.; Yan, S.; Ho, C.T.; Yang, C.S. Structural identification of two metabolites of catechins and their kinetics in human urine and blood after tea ingestion. Chem. Res. Toxicol., 2000, 13, 177-184.
190. Manach, C.; Morand, C.; Gil-Izquierdo, A.; Bouteloup-Demange, C.; Remesy, C. Bioavailability in humans of the flavanones hesperidin and narirutin after the ingestion of two doses of orange juice. Eur. J. Clin. Nutr., 2003, 57, 235-242.
191. Erlund, I.; Meririnne, E.; Alfthan, G.; Aro, A. Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. J. Nutr., 2001, 131, 235-241.
192. Scheline, R.R.CRC handbook of mammalian metabolism of plant compounds., CRC Press: Boca. Raton, FL.,1991.
193. Griffiths, L.A.; Smith, G.E. Metabolism of apigenin and related compounds in the rat. Metabolite formation in vivo and by the intestinal microflora in vitro. Biochem. J., 1972, 128, 901-911.
194. Rechner, A.R.; Smith, M.A.; Kuhnle, G.; Gibson, G.R.; Debnam, E.S.; Srai, S.K.; Moore, K.P.; Rice-Evans, C.A. Colonic metabolism of dietary polyphenols: Influence of structure on microbial fermentation products. Free Radic. Biol. Med., 2004, 36, 212-225.
195. Felgines, C.; Texier, O.; Morand, C.; Manach, C.; Scalbert, A.; Regerat, F.; Remesy, C. Bioavailability of the flavanone naringenin and its glycosides in rats. Am. J. Physiol. Gastrointest. Liver. Physiol., 2000, 279, G1148-1154.
196. Booth, A.N.; Jones, F.T.; De, E.F. Metabolic fate of hesperidin, eriodictyol, homoeridictyol, and diosmin. J. Biol. Chem., 1958, 230, 661-668.
197. Honohan, T.; Hale, R.L.; Brown, J.P.; Wingard, R.E., Jr. Synthesis and metabolic fate of hesperetin-3-14C. J. Agric. Food Chem., 1976, 24, 906-911.